Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 7/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 6/20 | 0.35 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL3710933 | 0.85 | CDK2 (0.39) | — | |
| SCHEMBL2946038 | 0.85 | AXL (0.47) | AXLMERTKTTK | |
| Hydrazine SCHEMBL2949213 | 0.83 | HRH4 (0.37) | HRH4 | |
| Ammonia Solution, Strong SCHEMBL3708348 | 0.74 | TTK (0.40) | TTK | |
| SCHEMBL3703315 | 0.74 | AXL (0.50) | AXLMERTKTTK | |
| SCHEMBL2946536 | 0.72 | AXL (0.44) | AXLMERTKTTK | |
| SCHEMBL4766705 | 0.71 | AXL (0.45) | AXLMERTKTTK | |
| SCHEMBL2951204 | 0.71 | AXL (0.47) | AXLMERTKTTK | |
| SCHEMBL3698227 | 0.71 | AXL (0.47) | AXLMERTKTTK | |
| SCHEMBL4766652 | 0.70 | AXL (0.45) | AXLMERTKTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | PRKDC 1140/4885AXL 2976/4885MERTK 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.